secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001558370-24-002780
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path Holdings FY2023 net loss $16.1M; cash drops to $1.1M from $10.4M
-------------------------------------------------------------------------

- Net loss $16.1M ($33.63 per share) vs $13.9M ($38.12 per share) in FY2022.
- Cash at Dec 31, 2023: $1.1M, down from $10.4M a year earlier.
- R&D expense rose to $11.6M from $9.2M on manufacturing and trial enrollment.
- Completed first dose cohort in Phase 1/1b trial of BP1002 for AML and Phase 1 trial for lymphoma/CLL.
- G&A fell to $4.2M from $4.7M; net cash used in ops $11.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024002780/0001558370-24-002780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024002780/bpth-20240308x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer